- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01653678
Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)
Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and Hypertension
Study Overview
Status
Conditions
Detailed Description
The human toll of hypertension is staggering, and effective preventive measures are needed. Studies suggest that inadequate vitamin D and omega-3 fatty acid levels may be involved in the development of hypertension through multiple pathways. Results from several small clinical trials suggest that these agents may have blood pressure lowering effects, however, larger trials using higher doses of both vitamin D and omega-3 fatty acids for the prevention of hypertension among people with normal blood pressure levels are lacking. The VITamin D and OmegA-3 TriaL (VITAL) provides a cost-effective setting to examine the effects of both study agents on changes in blood pressure and new diagnoses of hypertension.
VITAL Hypertension will test the following hypotheses: (1) whether vitamin D and fish oil supplementation lowers 24-hour blood ambulatory blood pressure (ABP) compared to placebo in a subcohort of 1,000 participants; (2) whether vitamin D and fish oil supplementation reduces the risk of incident hypertension compared to placebo among all randomized VITAL participants without baseline hypertension; and (3) whether vitamin D and fish oil supplementation favorably change hypertension-related biomarkers that are potential mechanisms linking vitamin D and omega-3 fatty acids with hypertension compared to placebo.
A representative subcohort of 1,000 VITAL participants without hypertension from selected major metropolitan areas throughout the US will be invited to participate in home-based study visits at baseline and 2 years follow-up. During these visits, participants will be asked to wear monitors to record 24-hour ABP measurements, provide fasting bloods, spot urine samples, and other clinical measurements. The visits will be conducted by Examination Management Services, Inc. (EMSI), a nationally based, clinical services provider. We will compare 2-year changes in ABP among those randomized to vitamin D and omega-3 fatty acid supplements versus those randomized to placebo. In addition, we will assess the 2-year changes in levels of clinically and mechanistically relevant biomarkers of hypertension compared the 2 treatment groups.
New diagnoses of hypertension among all VITAL participants will be ascertained on annual follow-up questionnaires. To strengthen our classification of hypertension status, we will supplement our questionnaire data with annual updates of hypertension information based upon outpatient diagnostic codes and medication prescription usage from the Centers for Medicare & Medicaid Services (CMS) database. Incidence of hypertension among those assigned to each active agent versus placebo will be compared.
In addition, baseline blood samples from 1,000 participants with new diagnoses of hypertension will be compared with those from 2,000 participants without hypertension to determine whether the effect of vitamin D and/or omega-3 fatty acid supplements on the incidence of hypertension is modified by baseline plasma levels of vitamin D or omega-3 fatty acids.
Results from VITAL Hypertension will provide important evidence to support or refute the potential preventive roles of vitamin D and omega-3 fatty acids on blood pressure and the development of hypertension.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vitamin D + fish oil
|
Other Names:
Omacor, 1 capsule per day.
Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
|
Active Comparator: Vitamin D + fish oil placebo
|
Other Names:
|
Active Comparator: Vitamin D placebo + fish oil
|
Omacor, 1 capsule per day.
Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
|
Placebo Comparator: Vitamin D placebo + fish oil placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in blood pressure
Time Frame: Two years
|
Change in 24-hour ambulatory blood pressure measurements among a subcohort of approximately 1,000 participants.
|
Two years
|
Incident hypertension
Time Frame: 5 years
|
Incidence of hypertension in the overall VITAL trial cohort.
|
5 years
|
Changes in 25-hydroxy-vitamin D levels
Time Frame: 2 years
|
Changes in a subcohort of approximately 1,000 participants.
|
2 years
|
Changes in fatty acid levels
Time Frame: 2 years
|
Changes in a subcohort of approximately 1,000 participants
|
2 years
|
Changes in biomarkers related to blood pressure
Time Frame: 2 years
|
Changes in a subcohort of approximately 1,000 participants
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Howard D. Sesso, ScD, MPH, Brigham and Women's Hospital
- Principal Investigator: John P. Forman, MD, Brigham and Women's Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-P-002880
- 1R01HL102122 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Fish oil placebo
-
Rigshospitalet, DenmarkDanish Child Cancer FoundationRecruitingLeukemia, Acute LymphoblasticDenmark
-
National Science Council, TaiwanCompletedMajor Depressive DisorderTaiwan
-
Wake Forest University Health SciencesWithdrawnCardiovascular Disease | Chronic Kidney DiseaseUnited States
-
University of CopenhagenCompletedQuality of Life | Cancer Cachexia | Side EffectsDenmark
-
University of CopenhagenAnjo A/SCompletedObesity | Cardiovascular Disease | Metabolic Syndrome | Growth | Blood Pressure
-
DSM Nutritional Products, Inc.Completed
-
National Center for Complementary and Integrative...Completed
-
Columbia UniversityGlaxoSmithKlineCompletedNon-Alcoholic Fatty Liver DiseaseUnited States
-
University of VirginiaNational Center for Complementary and Integrative Health (NCCIH)CompletedFatty Liver | Non-alcoholic SteatohepatitisUnited States
-
Indiana University School of MedicineCompletedEnd-Stage Renal Disease Patients on HemodialysisUnited States